Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major ...

Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half ...

Analysts were happy with batoclimab’s performance in the chronic autoimmune disorder, but Immunovant said it will continue to ...

Data from the Phase III MINT trial found that Uplizna demonstrated a greater reduction in Myasthenia Gravis Activities of ...

The companies reported Wednesday that batoclimab showed improvements in myasthenia gravis patients in a Phase 3 trial.

Gravis managing director William Macleod discusses why he believes investment trusts should not fall under the new regime’s ...

New late-stage study data shows that treatment with Amgen's Uplizna for a year improves disease symptoms in patients with ...

Switching to IMVT-1402 extends the head starts Immunovant has already ceded to its rivals. Argenx won FDA approval for ...

The company plans to use results from its Phase III myasthenia gravis study to support its pipeline candidate IMVT-1402 over ...

This week we are going to discuss a topic that we had briefly touched on earlier, the neurologic autoimmune conditions: myasthenia gravis and Lambert Eaton Syndrome (LEMS). To review: Myasthenia ...

The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the ...

The phase 3 MINT trial evaluated the efficacy and safety of the drug in both muscle-specific kinase autoantibody ...